Journal of Student Research,
Journal Year:
2023,
Volume and Issue:
12(3)
Published: Aug. 31, 2023
The
CRISPR
system
of
genetic
editing
has
been
a
breakthrough
in
all
fields
science
and
medicine,
including
that
cancer
research,
therapy,
diagnosis.
In
the
last
two
years,
research
narrowed
down
on
CRISPRs
ability
to
serve
as
tool
detect
oncogenes
patients
diagnose
quick
efficient
manner.
three
key
enzymes
(cas9,
cas12,
cas13)
are
revolutionary
for
medicine
trials.
MicroRNAs
(miRNAs)
short
noncoding
RNA
which
regulate
gene
expression
functions,
both
crucial
cell
functions.
However,
aberrant
miRNA
is
expressed
tumor
proliferation
diseases,
cancer.
Studies
have
shown
cancerous
levels
oncogenic
human
samples
through
variety
methods
such
CRISPR-Cas9/RNAi,
CRISPR/Cas12
RCA
coupling,
CRISPR/Cas13
exosome
Cas13a-Cas12a
amplification.
All
these
provide
extremely
high
sensitivity
specificity
detection
with
concentrations
below
1
fM.
This
paper
synthesis
current
mentioned
above
aid
further
CRISPR/Cas
systems
diagnosis
therapeutics.
Critical Reviews in Analytical Chemistry,
Journal Year:
2024,
Volume and Issue:
unknown, P. 1 - 17
Published: March 15, 2024
MicroRNA
(miRNA)
has
emerged
as
a
promising
biomarker
for
disease
diagnosis
and
potential
therapeutic
targets
drug
development.
The
detection
of
miRNA
can
serve
noninvasive
tool
in
diseases
predicting
prognosis.
CRISPR/Cas12a
system
great
nucleic
acid
due
to
its
high
sensitivity
specificity,
which
been
developed
be
versatile
acid-based
various
fields.
However,
conversion
from
RNA
DNA
with
or
without
amplification
operation
is
necessary
based
on
system,
because
dsDNA
containing
PAM
sequence
ssDNA
traditionally
considered
the
activator
Cas12a.
Until
recently,
direct
by
reported.
In
this
review,
we
provide
an
overview
evolution
biosensors
indirect
direct,
would
beneficial
development
CRISPR/Cas12a-based
sensors
better
performance
miRNA.
ACS Omega,
Journal Year:
2025,
Volume and Issue:
10(6), P. 6228 - 6233
Published: Feb. 8, 2025
MicroRNA
(miRNA)
is
pivotal
in
regulating
pathological
progression
and
may
serve
as
a
significant
biomarker
for
early
diagnosis,
treatment,
management
strategies
atherosclerosis.
This
study
produced
self-priming
amplification-accelerated
CRISPR/Cas
system-based
method
the
sensitive
selective
detection
of
miRNA
by
merging
Exo-III-assisted
target
recycling,
self-priming-mediated
chain
extension,
CRISPR/Cas12a
system.
The
sensor
comprises
three
stages:
(i)
creation
substrate
template
via
Exo-III
mediated
recycling
DNA
ligase
assisted
ligation;
(ii)
exponential
isothermal
reaction
facilitated
polymerase
signal
amplification;
(iii)
trans-cleavage
activity
after
recognizing
amplification
product
generates
signals.
We
employed
miRNA-21
target.
strategy
enables
without
use
primers,
unique
design
CRISPR/sgRNA
complex
efficiently
mitigates
background
interference.
can
recognize
single-base
mutant
homologous
sequences
demonstrate
steady
performance
complicated
biological
matrices.
has
been
effectively
to
precisely
assess
engineered
clinical
samples,
showcasing
its
potential
diagnostics
